ALK and non-small cell lung carcinoma: We questioned whether the generalized progression of EGFR-mutant and ALK-translocated NSCLC after an initial response to EGFR and ALK tyrosine kinase inhibitors (TKIs) in a clinical setting would alter the nature of the interaction between nintedanib and silibinin.